3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Colorectal Neoplasms
10
Breast Neoplasms
9
Colonic Neoplasms
6
Carcinoma, Non-Small-Cell Lung
5
Rectal Neoplasms
4
Lung Neoplasms
4
Head and Neck Neoplasms
4
Adenomatous Polyposis Coli
4
Sarcoma
3
Glioblastoma
3
Central Nervous System Neoplasms
3
Paranasal Sinus Neoplasms
2
Neoplasms
2
Mouth Neoplasms
2
Melanoma
2
Laryngeal Neoplasms
2
Gliosarcoma
2
Breast Carcinoma In Situ
2
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Triple Negative Breast Neoplasms
1
Tobacco Use Disorder
1
Stomatitis
1
Smoldering Multiple Myeloma
1
Smoking
1
Recurrence
1
Prostatic Neoplasms
1
Prostatic Hyperplasia
1
Precancerous Conditions
1
Interventions
Gemcitabine
13
Cisplatin
8
Capecitabine
8
Fluorouracil
5
pembrolizumab
4
Oxaliplatin
4
Sorafenib
3
Leucovorin
3
Erlotinib Hydrochloride
3
trametinib
2
regorafenib
2
durvalumab
2
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine
2
Magnetic Resonance Spectroscopy
2
Lapatinib
2
trifluridine tipiracil drug combination
1
tremelimumab
1
spartalizumab
1
seribantumab
1
olutasidenib
1
olaparib
1
devimistat
1
derazantinib
1
dehydroftorafur
1
cediranib
1
cabozantinib
1
Trifluridine
1
Trastuzumab
1
Therapeutics
1
Sutures
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Bile Duct Neoplasms
×
Celecoxib
×
Clear all
No trials found.